Viscofan(ES:VIS)
€56.60+0.70 (+1.25%)
ES:VIS
Viscofan stock drug pipeline
€56.60
At close:+0.70 (+1.25%)
Want to see ES:VIS full AI Analyst Report?
Viscofan (VIS) Drug Pipeline
33 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Vb-C01 Cellularised Patch | Heart Failure, Myocardial Infarction (Mi), Cabg-Patients | Phase I | Not Yet Recruiting | Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells | Apr 15, 2025 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Vb-C01 Cellularised Patch | Phase I | Heart Failure, Myocardial Infarction (Mi), Cabg-Patients | Not Yet Recruiting | Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells | Apr 15, 2025 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Viscofan SA (ES:VIS) have in its pipeline
Viscofan ES:VIS is currently developing the following drugs: Vb-C01 Cellularised Patch. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
